U.S. FDA Readies India Staffing; Says India Office To Enhance Speed And Effectiveness Of Regulatory Cooperation
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - U.S. FDA has hand picked a few top notch professionals from its global headquarters for positions at the newly planned Mumbai and New Delhi offices. Over the years, these officers have gained experience in drug regulation and investigations through several global postings
You may also be interested in...
With Closer Eye On Indian Units, U.S. FDA Names Altaf Lal As New Country Director
Four years after it established its first India base, U.S. FDA has effected a leadership change. The new chief is expected to play a double role as both guide and vigilant examiner.
Cipla’s Manufacturing Units In India Under U.S. FDA Lens; Inspectional Observations Issued
MUMBAI - U.S. FDA conducted inspections of three manufacturing sites belonging to Indian drug maker Cipla and issued nine to 10 "Inspectional Observations" on various manufacturing issues. The manufacturing sites inspected by FDA are in Goa, Kurkumbh and Bangalore
Cipla’s Manufacturing Units In India Under U.S. FDA Lens; Inspectional Observations Issued
MUMBAI - U.S. FDA conducted inspections of three manufacturing sites belonging to Indian drug maker Cipla and issued nine to 10 "Inspectional Observations" on various manufacturing issues. The manufacturing sites inspected by FDA are in Goa, Kurkumbh and Bangalore